Cytocore Inc (CYOE) 0.0221 $CYOE
MEDITE Files U.S. GAAP Financial Statements
Marketwire - Wed Jun 18, 7:26AM CDT
MEDITE Group, a leading developer and manufacturer of innovative, high-quality equipment and supplies for the cancer diagnostic segments of histology, pathology and cytology laboratories, announced that it filed Form 8-K with the Securities and Exchange Commission (SEC) for the audited financial results for the years ended December 31, 2012 and 2013. The Company also announced its unaudited results for the first quarter ended March 31, 2014. The results reflect the operations of MEDITE as a stand-alone company as they occurred prior to closing of the April 3, 2014 acquisition transaction with CytoCore, Inc. (OTCBB: CYOE).
MEDITE Signs Exclusive Marketing and Distribution Agreement With Medline
Marketwire - Thu Jan 16, 10:30AM CST
MEDITE Inc., a leading developer and manufacturer of innovative, high-quality equipment and supplies for histology, pathology and cytology laboratories, announced an exclusive marketing and distribution agreement with Medline Industries, Inc., based in Mundelein, Illinois. Under the agreement, Medline will have exclusive rights to market and distribute MEDITE's histology equipment and consumable product portfolio in the U.S. & Canada.
CytoCore to Acquire MEDITE
Marketwire - Mon Jan 13, 9:15AM CST
MEDITE Group, a leading developer of innovative, high-quality equipment and supplies for the cancer diagnostic segments of histology, pathology and cytology headquartered in Orlando, Florida, today announced that it has signed a definitive purchase agreement to be acquired by Chicago-based CytoCore, Inc. (OTCBB: CYOE), a late development stage bio molecular diagnostics company engaged in the design, development, and commercialization of cost-effective sample collection, clinical laboratory assay and instrument systems for the early detection and classification of cancer and for the assessment of the risk for cancer progression. The purchase agreement has been approved by the Board of Directors of both companies and is subject to standard and customary closing conditions and deliveries. The transaction is currently expected to close by March 15, 2014.
MEDITE Files U.S. GAAP Financial Statements
Marketwire - Wed Jun 18, 7:26AM CDT
MEDITE Group, a leading developer and manufacturer of innovative, high-quality equipment and supplies for the cancer diagnostic segments of histology, pathology and cytology laboratories, announced that it filed Form 8-K with the Securities and Exchange Commission (SEC) for the audited financial results for the years ended December 31, 2012 and 2013. The Company also announced its unaudited results for the first quarter ended March 31, 2014. The results reflect the operations of MEDITE as a stand-alone company as they occurred prior to closing of the April 3, 2014 acquisition transaction with CytoCore, Inc. (OTCBB: CYOE).
MEDITE Signs Exclusive Marketing and Distribution Agreement With Medline
Marketwire - Thu Jan 16, 10:30AM CST
MEDITE Inc., a leading developer and manufacturer of innovative, high-quality equipment and supplies for histology, pathology and cytology laboratories, announced an exclusive marketing and distribution agreement with Medline Industries, Inc., based in Mundelein, Illinois. Under the agreement, Medline will have exclusive rights to market and distribute MEDITE's histology equipment and consumable product portfolio in the U.S. & Canada.
CytoCore to Acquire MEDITE
Marketwire - Mon Jan 13, 9:15AM CST
MEDITE Group, a leading developer of innovative, high-quality equipment and supplies for the cancer diagnostic segments of histology, pathology and cytology headquartered in Orlando, Florida, today announced that it has signed a definitive purchase agreement to be acquired by Chicago-based CytoCore, Inc. (OTCBB: CYOE), a late development stage bio molecular diagnostics company engaged in the design, development, and commercialization of cost-effective sample collection, clinical laboratory assay and instrument systems for the early detection and classification of cancer and for the assessment of the risk for cancer progression. The purchase agreement has been approved by the Board of Directors of both companies and is subject to standard and customary closing conditions and deliveries. The transaction is currently expected to close by March 15, 2014.
